Capgemini Falls 2.81% at Close Despite Analysts’ Target Upgrades
Capgemini fell by 2.81% to 143.45 euros this Thursday, January 15, despite target price increases by BNP Paribas Exane to 170 euros, Oddo BHF to 180 euros, and Jefferies to 145 euros. The stock is in a technical consolidation phase after having risen by 20.65% over three months.
Market Context and Analyst Revisions
Capgemini closed this Thursday, January 15 at 143.45 euros, down by 2.81% from the previous day's price of 147.60 euros. This decline occurred in a mixed stock market environment for the French IT services specialist, which is now trading close to its 50-day moving average of 139.03 euros. However, the stock remains well above its 200-day moving average of 135 euros, confirming an underlying bullish trend despite today's correction. Jefferies raised its target price on Wednesday to 145 euros from 130 euros previously, maintaining a 'hold' recommendation, while Oddo BHF raised its target on Monday to 180 euros from 169 euros with an 'outperform' rating. BNP Paribas Exane also increased its target this Thursday to 170 euros with an 'outperform' recommendation. These target revisions contrast with Morgan Stanley's downgrade at the beginning of the week, which lowered its recommendation to 'underweight' and its target price to 142 euros. The RSI at 56 indicates a neutral situation, neither overbought nor oversold, consistent with a consolidation phase after the strong growth recorded over three months. The stock indeed shows a rise of 20.65% over this period, despite a decline of 2.48% over the last seven days and an annual drop of 7.48%.
Technical Analysis and Upcoming Financial Results
Technically, Capgemini is now trading between a support at 136.30 euros and a resistance at 151.85 euros, the latter having been tested at the beginning of January without being sustainably breached. The MACD, with a line at 1.69 slightly above its signal line at 1.66, displays a positive but slight histogram at 0.03, suggesting a weakening of the bullish momentum. The 20-day moving average at 145.24 euros serves as an immediate support level that the price just breached this Thursday, potentially paving the way for a return to the 50-day average. Investors remain on hold ahead of the publication of the annual results for 2025 scheduled for February 13, a crucial date following the revised growth targets announced in November. The group had then raised its growth forecast at constant exchange rates to between 2% and 2.5%, driven by demand in cloud and artificial intelligence. The divergence of opinions among analysts, with targets ranging from 142 euros by Morgan Stanley to 180 euros by Oddo BHF, reflects the uncertainty surrounding the recovery trajectory of the group in a sector facing competitive pressures and accelerated transformation by generative AI.